009420.KS Hanall Biopharma Co., Ltd.
KSCHealthcareAs of 2026-08-09 03:24
Why 009420.KS matters now
Hanall Biopharma Co., Ltd. (009420.KS) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩54,100.00 with -2.70% on the session and ₩2.83T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E -112.22, gross margin 37.0%, and operating margin 2.5%.
Valuation
P/E (TTM)
-112.22
PEG
—
P/B
17.41
P/S
16.92
EV/EBITDA
-195.38
DCF Value
—
FCF Yield
0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
37.0%
Operating Margin
2.5%
Net Margin
-15.3%
ROE
-15.6%
ROA
-10.2%
ROIC
1.8%
Listing Info
Market
Korea
Exchange
KSC
Currency
KRW
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
KR
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.